$10.07
-0.19 (-1.85%)
Open$10.00
Previous Close$10.26
Day High$10.13
Day Low$9.64
52W High$43.85
52W Low$7.15
Volume—
Avg Volume279.3K
Market Cap160.34M
P/E Ratio—
EPS$-17.32
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
-8.5% upside
Current
$10.07
$10.07
Target
$9.21
$9.21
$5.69
$9.21 avg
$10.08
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 192.03M | 167.30M | 26.00M |
| Net Income | -358,042,066 | -280,743,909 | 1.01M |
| Profit Margin | -186.5% | -177.1% | 3.9% |
| EBITDA | -283,013,492 | -234,241,869 | 1.64M |
| Free Cash Flow | — | — | 646.8K |
| Rev Growth | +14.8% | +14.8% | +22.0% |
| Debt/Equity | 4.05 | 4.05 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |